Same reason as other strategies/tactics are not explained to the market. They don't want regulators etc reading their releases as that could make negotiating favourable regulatory outcomes more difficult. Its not really a good strategy anymore if everyone knows about it...
It's really up to the investor to see that this is a very well run company, and to back the management team who clearly know what they're doing.
Ann: SCENESSE European Orphan Drug Designation for VP, page-13
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.60 |
Change
-0.910(5.87%) |
Mkt cap ! $727.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $2.399M | 162.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 60 | $14.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 42 | 5 |
View Market Depth
| Last trade - 11.09am 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |